Windlas Biotech Limited (BOM:543329)

India flag India · Delayed Price · Currency is INR
816.55
+8.30 (1.03%)
At close: Jun 19, 2026
Market Cap16.84B -11.7%
Revenue (ttm)9.04B +19.0%
Net Income664.56M +9.0%
EPS31.15 +7.9%
Shares Out n/a
PE Ratio25.34
Forward PEn/a
Dividend5.80 (0.71%)
Ex-Dividend DateJul 21, 2025
Volume2,190
Open810.00
Previous Close808.25
Day's Range799.70 - 829.00
52-Week Range699.35 - 1,095.00
Betan/a
AnalystsStrong Buy
Price Targetn/a
Earnings DateAug 5, 2026

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz... [Read more]

Industry Pharmaceutical Preparations
Founded 2001
Employees 1,346
Stock Exchange Bombay Stock Exchange
Ticker Symbol 543329
Full Company Profile

Financial Performance

In fiscal year 2026, Windlas Biotech's revenue was 9.04 billion, an increase of 18.98% compared to the previous year's 7.60 billion. Earnings were 664.56 million, an increase of 8.95%.

Financial Statements